Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam. 2018

Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
Pasteur Institute, Ho Chi Minh City, Vietnam.

We tested a new A/H1N1 inactivated influenza vaccine (IIV) manufactured by Institute of Vaccines and Medical Biologics (IVAC), Vietnam in 48 adults in a Phase 1, double-blinded, randomized, placebo-controlled trial. Two doses of unadjuvanted vaccine or placebo were administered three weeks apart. The vaccine was well tolerated with only transient mild local reactions and low-grade fever in a small proportion of the subjects. One serious adverse event considered unrelated to the study product was reported. The IVAC vaccine proved to be highly immunogenic with 91 percent (95% CI: 0.78, 1) of the subjects developing a ≥4 fold immune responses by hemagglutination inhibition (HAI) assay, and 96 percent (95% CI: 0.78, 1) by the microneutralization (MN) assay. Post-vaccination geometric mean titers (GMTs) were 283.7 (95% CI: 161.7, 497.5) in the HAI and 725.7 (95% CI: 411.3, 1280.3) in the MN assay. These promising results merit further development of the vaccine. ClinicalTrials.gov number: NCT01507779.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006385 Hemagglutination Inhibition Tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
January 2011, Vaccine,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
January 2012, Vaccine,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
September 2011, The Journal of infectious diseases,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
January 2012, The oncologist,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
January 2011, Voprosy virusologii,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
January 2011, PloS one,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
December 2010, Expert review of vaccines,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
August 2019, Vaccine,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
January 2011, Expert review of vaccines,
Ho Vinh Thang, and Vu Minh Huong, and John C Victor, and Cao Bao Van, and Nguyen Tuyet Nga, and Le Van Be, and Nguyen Phu Cuong, and Vadim Tsvetnitsky, and Kathleen M Neuzil, and Maureen Power, and Jorge Flores
August 2010, Vaccine,
Copied contents to your clipboard!